Literature DB >> 12576380

Surgical treatment of malignant pleural mesothelioma: a review.

Serge van Ruth1, Paul Baas, Frans A N Zoetmulder.   

Abstract

Despite many years of clinical research, there is still no effective therapy for malignant pleural mesothelioma (MPM). Untreated, the prognosis is poor, with a median survival of < 1 year. Single-agent or combination chemotherapy as well as radiotherapy have not shown persistent improvements in response or survival. In general, MPM is a disease confined to the pleural cavity for a long time before metastasizing. Therefore, focus on local treatment seems rational. Surgical resection has been considered the mainstay of treatment by some. However, surgery alone results in high recurrence rates, and the survival benefit remains questionable. In recent years, the emphasis has been on surgery combined with adjuvant therapies. In this article, the present state of surgical management of MPM will be reviewed.

Entities:  

Mesh:

Year:  2003        PMID: 12576380     DOI: 10.1378/chest.123.2.551

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  16 in total

Review 1.  Malignant pleural mesothelioma: update on treatment options with a focus on novel therapies.

Authors:  Andrew R Haas; Daniel H Sterman
Journal:  Clin Chest Med       Date:  2013-01-17       Impact factor: 2.878

2.  Quantitative measurement of lung reexpansion in malignant pleural mesothelioma patients undergoing pleurectomy/decortication.

Authors:  William F Sensakovic; Samuel G Armato; Adam Starkey; Hedy L Kindler; Wickii T Vigneswaran
Journal:  Acad Radiol       Date:  2010-12-10       Impact factor: 3.173

3.  Heparanase and basic fibroblast growth factor are co-expressed in malignant mesothelioma.

Authors:  Ben Davidson; Lina Vintman; Eyal Zcharia; Carlos Bedrossian; Aasmund Berner; Søren Nielsen; Neta Ilan; Israel Vlodavsky; Reuven Reich
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

4.  The evolution of multimodality therapy for malignant pleural mesothelioma.

Authors:  Marjorie G Zauderer; Lee M Krug
Journal:  Curr Treat Options Oncol       Date:  2011-06

5.  Diffuse malignant pleural mesothelioma: a multi-institutional clinicopathological study.

Authors:  Akira Iyoda; Toshikazu Yusa; Chikabumi Kadoyama; Kazuyoshi Sasaki; Hideki Kimura; Hisami Yamakawa; Mitsutoshi Shiba; Takehiko Fujisawa; Ichiro Yoshino
Journal:  Surg Today       Date:  2008-10-29       Impact factor: 2.549

Review 6.  Management of malignant pleural effusion.

Authors:  Jack A Kastelik
Journal:  Lung       Date:  2013-01-13       Impact factor: 2.584

7.  Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma.

Authors:  Lilach Kleinberg; Vivi Ann Flørenes; Martina Skrede; Hiep Phuc Dong; Søren Nielsen; Michael T McMaster; Jahn M Nesland; Ie-Ming Shih; Ben Davidson
Journal:  Virchows Arch       Date:  2006-03-16       Impact factor: 4.064

Review 8.  Malignant mesothelioma: current status and perspective in Japan and the world.

Authors:  Seiki Hasegawa; Fumihiro Tanaka
Journal:  Gen Thorac Cardiovasc Surg       Date:  2008-07-08

9.  Lysyl oxidase-like 4 is alternatively spliced in an anatomic site-specific manner in tumors involving the serosal cavities.

Authors:  Shulamit Sebban; Ben Davidson; Reuven Reich
Journal:  Virchows Arch       Date:  2008-11-18       Impact factor: 4.064

10.  Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.

Authors:  Lee M Krug; Harvey I Pass; Valerie W Rusch; Hedy L Kindler; David J Sugarbaker; Kenneth E Rosenzweig; Raja Flores; Joseph S Friedberg; Katherine Pisters; Matthew Monberg; Coleman K Obasaju; Nicholas J Vogelzang
Journal:  J Clin Oncol       Date:  2009-04-13       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.